These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23585661)

  • 1. The prevalence and natural history of pituitary hemorrhage in prolactinoma.
    Sarwar KN; Huda MS; Van de Velde V; Hopkins L; Luck S; Preston R; McGowan BM; Carroll PV; Powrie JK
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2362-7. PubMed ID: 23585661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
    Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma.
    Schmid C; Goede DL; Hauser RS; Brändle M
    Swiss Med Wkly; 2006 Apr; 136(15-16):254-8. PubMed ID: 16708311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macroprolactinomas and epilepsy.
    Deepak D; Daousi C; Javadpour M; MacFarlane IA
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):503-7. PubMed ID: 17371466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients.
    Domingue ME; Devuyst F; Alexopoulou O; Corvilain B; Maiter D
    Clin Endocrinol (Oxf); 2014 May; 80(5):642-8. PubMed ID: 24256562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute complications of dopamine agonist treatment for macroprolactinoma - how uncommon?
    Nadesapillai S; Balcere I; Kaye AH; Tress BM; Colman PG
    J Clin Neurosci; 2004 Nov; 11(8):825-8. PubMed ID: 15519856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis.
    Arya VB; Aylwin SJB; Hulse T; Ajzensztejn M; Kalitsi J; Kalogirou N; Bodi I; Thomas N; Hampton T; Kapoor RR; Buchanan CR
    Clin Endocrinol (Oxf); 2021 Mar; 94(3):413-423. PubMed ID: 33340135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary apoplexy within a macroprolactinoma.
    Watt A; Pobereskin L; Vaidya B
    Nat Clin Pract Endocrinol Metab; 2008 Nov; 4(11):635-41. PubMed ID: 18797434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
    Kars M; Pereira AM; Smit JW; Romijn JA
    Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of anaemia associated with prolactin-secreting pituitary tumours in men.
    Iglesias P; Castro JC; Díez JJ
    Int J Clin Pract; 2011 Jun; 65(6):669-73. PubMed ID: 21564439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
    Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
    Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
    Delgrange E; Duprez T; Maiter D
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of subclinical haemorrhage on the pituitary gland in patients with pituitary adenomas.
    Kinoshita Y; Tominaga A; Usui S; Arita K; Sugiyama K; Kurisu K
    Clin Endocrinol (Oxf); 2014 May; 80(5):720-5. PubMed ID: 24125536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactinomas diagnosed in the postmenopausal period: Clinical phenotype and outcomes.
    Santharam S; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Webster R; Karavitaki N
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):508-514. PubMed ID: 28626987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia.
    Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome.
    Iglesias P; Bernal C; Villabona C; Castro JC; Arrieta F; Díez JJ
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):281-7. PubMed ID: 22288612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.